Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXICAPS vs LANOXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation (rate control)
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation and atrial flutter for rate control (off-label: paroxysmal supraventricular tachycardia)
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Primarily renal excretion as unchanged drug; minor hepatic metabolism via CYP3A4 and glucuronidation.
Primarily hepatic via CYP3A4 and renal excretion of unchanged drug; undergoes biliary excretion and enterohepatic recirculation.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
Digitoxin is approximately 90-97% bound to serum proteins, primarily albumin.
25-30% bound primarily to albumin.
Volume of distribution is approximately 0.6 L/kg, indicating extensive tissue binding and distribution; the large Vd reflects accumulation in tissues like myocardium and skeletal muscle.
Vd approximately 6-7 L/kg; indicates extensive tissue binding, particularly to cardiac muscle.
Oral bioavailability is virtually 100% (90-100%) for Lanoxicaps (digitoxin), with consistent absorption from the gastrointestinal tract.
Oral: 60-80%; Intravenous: 100%.
For e GFR <50 m L/min, reduce dose by 50% or extend dosing interval: e GFR 35-50 m L/min: 0.125 mg every 24-48 hours; e GFR 10-34 m L/min: 0.125 mg every 48-72 hours; e GFR <10 m L/min: 0.125 mg every 72-96 hours.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or use 0.125 mg every 48 hours; GFR <10 m L/min: reduce dose by 75% or use 0.0625 mg daily; monitor digoxin levels.
Severe hepatic impairment (Child-Pugh class C) requires dose reduction by 50-75%; monitor digoxin levels. Avoid in fulminant hepatitis.
No specific Child-Pugh based dose adjustment; use caution in severe hepatic impairment due to potential toxicity; monitor levels.
Neonates: 4-6 mcg/kg/day; Infants: 6-10 mcg/kg/day; Children 1-5 years: 10-15 mcg/kg/day; Children 6-12 years: 8-10 mcg/kg/day; Adolescents: 3-5 mcg/kg/day. All doses given orally.
Loading dose: 10-15 mcg/kg orally divided every 8 hours over 24 hours; maintenance: 5-10 mcg/kg/day orally in 2 divided doses; maximum 0.25 mg/day.
Start at lower dose (0.0625-0.125 mg daily) due to reduced renal function and lean body mass; monitor serum creatinine and digoxin levels.
Start with 0.0625-0.125 mg orally daily; adjust based on renal function and drug levels; due to decreased lean body mass and renal clearance.
Toxicity: Narrow therapeutic index; monitor serum levels; avoid in patients with ventricular fibrillation or outflow obstruction.
None; however, toxicity is common and potentially fatal. Not a formal black box warning due to age of drug.
Monitor for digitalis toxicity (anorexia, nausea, visual disturbances, arrhythmias). Adjust dose in renal impairment, hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism.
Toxicity risk: hypokalemia, hypomagnesemia, hypercalcemia increase sensitivity,Renal impairment requires dose adjustment,Digoxin immune Fab for life-threatening overdose,Pregnancy category C,Monitor serum levels and ECG
Ventricular fibrillation,Hypersensitivity to digitalis glycosides,Wolff-Parkinson-White syndrome with atrial fibrillation,Second- or third-degree AV block (without pacemaker),Hypertrophic obstructive cardiomyopathy
Hypersensitivity,Ventricular fibrillation,AV block (unless pacemaker present),Wolff-Parkinson-White syndrome with atrial fibrillation,Hypertrophic obstructive cardiomyopathy,Hypokalemia or hypercalcemia (relative)
High-fiber foods (bran, oats) and certain foods containing pectin can reduce digoxin absorption; take Lanoxicaps on an empty stomach or at least 1 hour before or 2 hours after meals. St. John's Wort may decrease digoxin levels. Avoid licorice root, which can cause hypokalemia and increase toxicity. Consistent dietary potassium intake is important; avoid potassium supplements unless directed.
High-fiber foods (bran) may decrease absorption; take digoxin 2 hours before or after high-fiber meals. Potassium-rich foods (bananas, oranges, spinach) can affect toxicity risk; maintain consistent intake. Avoid excessive licorice (glycyrrhizin can cause hypokalemia). Grapefruit juice may increase digoxin absorption; avoid large amounts.
FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal bradycardia, low birth weight; therapeutic levels near toxic for fetus. Use only if maternal benefit outweighs risk.
Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Risk of fetal toxicity (bradycardia, arrhythmias) if maternal serum levels are supratherapeutic; therapeutic maternal levels are generally safe. Chronic use may be associated with reduced birth weight.
Digoxin is excreted into breast milk at low levels (M/P ratio ~0.6–0.9); infant exposure is subtherapeutic. Considered compatible with breastfeeding, but monitor infant for signs of digoxin toxicity (e.g., arrhythmias, nausea).
Digoxin is excreted into breast milk in low concentrations. M/P ratio approximately 0.6–0.9. At typical maternal doses (0.125–0.5 mg/day), the estimated infant dose is less than 10% of the weight-adjusted neonatal maintenance dose, usually considered compatible with breastfeeding. Monitor infant for signs of digoxin toxicity (bradycardia, poor feeding, vomiting).
Increased volume of distribution and renal clearance in pregnancy may lower digoxin levels; dose adjustment often needed in third trimester. Monitor levels frequently and increase dose if subtherapeutic. Postpartum, reduce dose as clearance normalizes.
Pregnancy increases glomerular filtration rate (GFR) and volume of distribution, which may lower serum digoxin concentrations; dose adjustments are often needed. Monitor serum levels and adjust dose to maintain therapeutic range (0.5–2.0 ng/m L). Consider increasing dose by 30-50% in later pregnancy if levels are low; postpartum dose may need reduction to prepregnancy levels.
Lanoxicaps (digoxin) has a high bioavailability (90-100%) compared to standard digoxin tablets; adjust dose when switching formulations to avoid toxicity. Monitor renal function and electrolytes (especially potassium, magnesium, calcium) closely; hypokalemia increases digoxin toxicity risk. Digoxin toxicity can present with arrhythmias (e.g., bidirectional ventricular tachycardia, atrial tachycardia with block) and visual disturbances (yellow-green halos). Use digoxin-specific Fab fragments for life-threatening toxicity. Therapeutic drug monitoring: draw levels at least 6-8 hours after dose; target 0.5-0.9 ng/m L for heart failure, 0.8-2.0 ng/m L for atrial fibrillation.
Check serum digoxin level 6-8 hours after last dose; therapeutic range 0.5-2.0 ng/m L. Hypokalemia, hypomagnesemia, hypercalcemia increase toxicity risk. Use with caution in renal impairment (reduce dose). Monitor for bradycardia and arrhythmias. Avoid in patients with AV block (except pacemaker) or hypertrophic cardiomyopathy. Loading dose: 10-15 mcg/kg lean body weight. Maintenance: 0.125-0.25 mg daily. Consider drug interactions with amiodarone, verapamil, quinidine, and macrolides.
Take exactly as prescribed; do not miss doses or double up. If a dose is missed, skip it unless close to next dose.,Do not switch between Lanoxicaps and standard digoxin tablets without your doctor's approval due to different absorption.,Report symptoms of toxicity: nausea, vomiting, diarrhea, confusion, visual changes (blurred vision, yellow-green halos), or irregular heartbeat.,Keep regular appointments for blood tests to monitor digoxin levels, kidney function, and electrolytes.,Avoid over-the-counter medications, especially antacids, kaolin-pectin, and some laxatives, which can affect absorption.,Maintain consistent dietary intake of potassium-rich foods (bananas, oranges) and avoid extreme changes in diet.
Take digoxin exactly as prescribed, usually once daily. Do not miss doses or double up.,Monitor pulse before each dose; hold and contact prescriber if heart rate <60 bpm.,Report symptoms of toxicity: nausea, vomiting, diarrhea, blurred vision, yellow-green halos, confusion, or irregular heartbeat.,Avoid over-the-counter antacids, laxatives, or kaolin-pectin; they reduce absorption. Take digoxin 2 hours apart from such products.,Maintain consistent intake of potassium-rich foods (bananas, oranges) unless otherwise instructed. Avoid excessive salt substitutes.,Keep all appointments for blood tests (digoxin levels, potassium, kidney function).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXICAPS vs LANOXIN, answered by our medical review team.
LANOXICAPS is a Cardiac Glycoside that works by Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.. LANOXIN is a Cardiac Glycoside that works by Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXICAPS and LANOXIN depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXICAPS is: 0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.. The standard adult dose of LANOXIN is: 0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXICAPS and LANOXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXICAPS is classified as Category C. FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal . LANOXIN is classified as Category C. Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.